The shares are listed on the Nasdaq Global Market

Davis Polk advised the representatives of the several underwriters in connection with Oculis Holding AG’s debut SEC-registered offering of an aggregate of 35,000,000 ordinary shares. The offering resulted in gross proceeds of $40.25 million for Oculis. Oculis’s ordinary shares are listed on the Nasdaq Global Market under the symbol “OCS.”

Oculis is a global biopharmaceutical company headquartered in Lausanne, Switzerland. Its mission is to save sight, improve eye care and address medical needs with breakthrough innovations. Oculis’s pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments, focusing on areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED) and neuro-retina indications such as glaucoma, affecting growing patient populations.

The Davis Polk corporate team included partner Derek Dostal and associates Arisa Akashi Sin, Steven Glendon and Wenyi Xu. The tax team included partner Ethan R. Goldman and associate Eitan Ulmer. The intellectual property team included partner David R. Bauer, counsel Christopher C. Woller and associate Adrian Rabin. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.